Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1993-11-26
1997-04-15
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
4242181, 4242211, 4242041, 424815, A61K 3900, A61K 31193, A61K 3938, A61K 3912
Patent
active
056206917
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The invention relates to the isolation, characterization and utilization of the causative agent of the Mystery Swine Disease (MSD). The invention utilizes the discovery of the agent causing the disease and the determination of its genome organization, the genomic nucleotide sequence and the proteins encoded by the genome, for providing protection against and diagnosis of infections, in particular protection against and diagnosis of MSD infections, and for providing vaccine compositions and diagnostic kits, either for use with MSD or with other pathogen-caused diseases.
BACKGROUND
In the winter and early spring of 1991, the Dutch pig industry was struck by a sudden outbreak of a new disease among breeding sows. Most sows showed anorexia, some aborted late in gestation (around day 110), showed stillbirths or gave birth to mummified fetuses and some had fever. Occasionally, sows with bluish ears were found, therefore the disease was commonly named "Abortus Blauw". The disease in the sows was often accompanied by respiratory distress and death of their young piglets, and often by respiratory disease and growth retardation of older piglets and fattening pigs.
The cause of this epizootic was not known, but the symptoms resembled those of a similar disease occurring in Germany since late 1990, and resembled those of the so-called "Mystery Swine Disease" as seen since 1987 in the mid-west of the United States of America and in Canada (Hill, 1990). Various other names have been used for the disease, in Germany it is known as "Seuchenhafter Sp atabort der Schweine", and in North-America it is also known as "Mystery Pig Disease", "Mysterious Reproductive Syndrome", and "Swine Infertility and Respiratory Syndrome". In North-America, Loula (1990) described the general clinical signs as:
No causative agent has as yet been identified, but encephalomyocarditis virus (EMCV), porcine parvo virus (PPV), pseudorabies virus (PRV), swine influenza virus (SIV), bovine viral diarrhea virus (BVDV), hog cholera virus (HCV), porcine entero viruses (PEV), an influenza-like virus, chlamidiae, leptospirae, have all been named as possible cause (Loula, 1990; Mengeling and Lager, 1990; among others).
SUMMARY OF THE INVENTION
The invention provides a composition of matter comprising isolated Lelystad Agent which is the causative agent of Mystery Swine Disease, said Lelystad Agent essentially corresponding to the isolate Lelystad Agent (CDI-NL-2.91) deposited 5 Jun. 1991 with the Institut Pasteur, Collection Nationale de Cultures De Microorganismes (C.N.C.M.) 25, rue du Docteur Roux, 75724-Paris Cedex 15, France, deposit number I-1102. The words "essentially corresponding" refer to variations that occur in nature and to artificial variations of Lelystad Agent, particularly those which still allow detection by techniques like hybridization, PCR and ELISA, using Lelystad Agent-specific materials, such as Lelystad Agent-specific DNA or antibodies.
The composition of matter may comprise live, killed, or attenuated isolated Lelystad Agent; a recombinant vector derived from Lelystad Agent; an isolated part or component of Lelystad Agent; isolated or synthetic protein, (poly)peptide, or nucleic acid derived from Lelystad Agent; recombinant nucleic acid which comprises a nucleotide sequence derived from the genome of Lelystad Agent; a (poly)peptide having an amino acid sequence derived from a protein of Lelystad Agent, the (poly)peptide being produced by a cell capable of producing it due to genetic engineering with appropriate recombinant DNA; an isolated or synthetic antibody which specifically recognizes a part or component of Lelystad Agent; or a recombinant vector which contains nucleic acid comprising a nucleotide sequence coding for a protein or antigenic peptide derived from Lelystad Agent.
On the DNA level, the invention specifically provides a recombinant nucleic acid, more specifically recombinant DNA, which comprises a Lelystad Agent-specific nucleotide sequence shown in FIG. 1 which includes FIGS. 1a thro
REFERENCES:
patent: 5476778 (1995-12-01), Chladek et al.
patent: 5510258 (1996-04-01), Sanderson et al.
Terpstra et al "Experimental reproduction of porcine epidemic abortion . . . " The Veterinary Quarterly, vol. 13, No. 3, Jul. 1991, pp. 131-136.
"Pathological, ultrastructural, and immunohistochemical changes caused by . . . " The Veterinary Quarterly, vol. 13, No. 3, Jul. 1991, pp. 137-143.
Wensvoort et al "Blue ear" disease, The Veterinary Record, vol. 128, No. 128, Jun. 15, 1991, column, 1, letter, p. 574.
Wensvoort et al "Mystery swine disease in the Netherlands: the isolation of Lelystad virus", The Veterinary Quarterly, vol. 13, No. 3, Jul. 1991, pp. 121-130.
Saif LJ. Veterinary Microbiology 37:285-297, 1993.
Scott FW. Adv. Exp. Med. Biol 218:569-576, 1987.
Martin et al, Can J Comp Med 49(1):1-9, 1985.
Beale AJ, "Vaccines and antiviral drugs", Topley & Wilson's Principles of bacteriology, virology and immunity, vol. 4, Ch. 86, pp. 147-161.
Brinton MA, "Lactate Dehydrogenase-Elevating, Equine Arteritis and Lelystad Viruses", Encyclopedia of Virology, vol. 2, pp. 763-771.
Christianson et al., "Porcine reproductive and respiratory syndrome: A review", Swine Health and Production, vol. 2, No. 2, pp. 10-28, Mar. and Apr., 1994.
Den Boon et al., "Equine Arteritis Virus Is Not a Togavirus but Belongs to the Coronaviruslike Superfamily", Journal of Virology, vol. 65, No. 6, pp. 2910-2920, 1991.
Dykhuizen et al., "Determining the Economic Impact of the 'New' Pig Disease", Porcine Reproductive and Respiratory Syndrome, A Report on the Seminar Held in Brussels on 4-5 Nov. 1991 and Organized by the European Commission, pp. 53-60.
Fenner et al., "Viral Genetics and Evolution", Veterinary Virology, Ch. 5, pp. 89-95.
Fenner et al., "Immunization against Viral Diseases", Veterinary Virology, Ch. 14, pp. 265-271.
Meredith MJ, "Porcine Reproductive and Respiratory Syndrome (PRRS)", Pig Disease Information Center, 1st North American Edition, Universtiy of Cambridge, pp. 1-57, Aug. 1994.
Polson et al., "An evalutation of the financial impact of Porcine Reproductive and Respiratory Syndrome (PRRS) in nursery pigs", Proceedings of the 13th International Pig Veterinary Society Congress, p. 31, Jun. 1994.
Polson DD, "Answers to Your Questions on PRRS", NOBL Laboratories, 18 pages.
Polson DD, "RespPRRS A PRRS Vaccine Review", NOBL Laboratories, 22 pages.
Snijder et al., "The carboxyl-terminal part of the putative Berne virus polymerase is expressed by ribosomal frameshifting and contains sequence motifs which indicate that toro-and coronaviruses are evolutionarily related", Nucleic Acids Research, vol. 18, No. 15, pp. 4535-4542, 1990.
Timony PJ, "Equine Viral Arteritis", Manual of Standards for Diagnostic Tests and Vaccines, pp. 493-499, 1992.
"Revision of the taxonomy of the Coronavirus, Torovirus and Arterivirus genera", Arch Virol, vol. 135, pp. 227-239, Virology Division News, 1994.
Wenswoort et al., "Antigenic comparison of Lelystad virus and swine infertility and respiratory syndrome (SIRS) virus", J. Vet Diagn Invest, vol. 4, pp. 134-138, 1992.
Wenswoort et al., "The Porcine Reproductive and Respiratory Syndrome; Characteristics and diagnosis of the causative virus", Veterinary Biotechnology Newsletter, vol. 3, pp. 113-120, 1993.
Murphy et al "Immunization Against Virus" in Virology 2nd ed, vol. 1, Fields et al eds. Raven Press, N.Y. 1990 pp. 469-502.
Notice of Opposition by Akzo Nobel against European Patent No. 0 587 780, Nov. 28, 1995, EP.
Notice of Opposition by Cyandmid Iberica against European Patent No. 0 587 780, Nov. 28, 1995, EP.
Abstracts of Papers Presented at the 71st Annual Meeting of the Conference of Research Workers in Animal Disease, No.'s 1-6, Nov. 5,6, 1990, 2 pages.
"Advances in Veterinary Virology 2", Veterinary Microbiology, 33(1992), pp. 185-193.
Boursnell et al., "Completion of the Sequence of the Genome of the Coronavirus Avian Infectious Bronchitis Virus", Journal of General Virology 68, 1986, pp. 57-77.
Christianson et al., "Experimental
Pol Joannes M. A.
Terpstra Catharinus
Wensvoort Gert
Housel James C.
Minnifield N. M.
Stichting Centraal Diergeneeskundig Instituut
LandOfFree
Causative agent of the mystery swine disease, vaccine compositio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Causative agent of the mystery swine disease, vaccine compositio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Causative agent of the mystery swine disease, vaccine compositio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-358847